JP2021500025A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500025A5 JP2021500025A5 JP2020521880A JP2020521880A JP2021500025A5 JP 2021500025 A5 JP2021500025 A5 JP 2021500025A5 JP 2020521880 A JP2020521880 A JP 2020521880A JP 2020521880 A JP2020521880 A JP 2020521880A JP 2021500025 A5 JP2021500025 A5 JP 2021500025A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- stands
- galnac
- nucleotides
- positions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023151506A JP7645323B2 (ja) | 2017-10-20 | 2023-09-19 | B型肝炎感染の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762575358P | 2017-10-20 | 2017-10-20 | |
| US62/575,358 | 2017-10-20 | ||
| PCT/US2018/056801 WO2019079781A2 (en) | 2017-10-20 | 2018-10-19 | METHODS OF TREATING HEPATITIS B TYPE INFECTIONS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023151506A Division JP7645323B2 (ja) | 2017-10-20 | 2023-09-19 | B型肝炎感染の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500025A JP2021500025A (ja) | 2021-01-07 |
| JP2021500025A5 true JP2021500025A5 (cg-RX-API-DMAC7.html) | 2023-07-21 |
| JP7353276B2 JP7353276B2 (ja) | 2023-09-29 |
Family
ID=66173915
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521880A Active JP7353276B2 (ja) | 2017-10-20 | 2018-10-19 | B型肝炎感染の治療方法 |
| JP2023151506A Active JP7645323B2 (ja) | 2017-10-20 | 2023-09-19 | B型肝炎感染の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023151506A Active JP7645323B2 (ja) | 2017-10-20 | 2023-09-19 | B型肝炎感染の治療方法 |
Country Status (30)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3684377B1 (en) | 2017-10-20 | 2022-12-07 | Dicerna Pharmaceuticals, Inc. | Methods for treating hepatitis b infection |
| BR112021000538A2 (pt) | 2018-07-13 | 2021-04-06 | F. Hoffmann-La Roche Ag | Oligonucleotídeos para modular a expressão de rtel1 |
| US20220389430A1 (en) * | 2019-10-02 | 2022-12-08 | Dicema Pharmaceuticals, Inc. | Chemical modifications of small interfering rna with minimal fluorine content |
| CN114867856A (zh) * | 2019-12-19 | 2022-08-05 | 豪夫迈·罗氏有限公司 | Saraf抑制剂用于治疗乙型肝炎病毒感染的用途 |
| EP4081217A1 (en) * | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
| EP4081639A1 (en) * | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv |
| CA3187388A1 (en) * | 2020-07-27 | 2022-02-03 | Jin Hong | Hbv binding oligonucleotides and methods of use |
| JP2023536999A (ja) * | 2020-08-05 | 2023-08-30 | エフ. ホフマン-ラ ロシュ アーゲー | B型肝炎患者のオリゴヌクレオチド処置 |
| KR102798766B1 (ko) * | 2020-12-18 | 2025-04-23 | 올릭스 주식회사 | HBV 발현을 억제하는 RNAi 제제 및 이의 용도 |
| CN114853829A (zh) * | 2021-02-05 | 2022-08-05 | 上海拓界生物医药科技有限公司 | 一种核酸配体、其缀合物、制备方法及用途 |
| MX2023012048A (es) * | 2021-04-12 | 2023-10-23 | Boehringer Ingelheim Int | Composiciones y metodos para inhibir cetohexoquinasa (khk). |
| CN113171371B (zh) * | 2021-04-13 | 2022-01-25 | 厦门甘宝利生物医药有限公司 | 一种抑制乙型肝炎病毒基因表达的rna抑制剂及其应用 |
| IL307154A (en) * | 2021-04-19 | 2023-11-01 | Novo Nordisk As | Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression |
| CN117280031A (zh) * | 2021-04-19 | 2023-12-22 | 诺和诺德股份有限公司 | 用于抑制核受体亚家族1组h成员3(nr1h3)表达的组合物和方法 |
| AU2022384619A1 (en) | 2021-11-11 | 2024-04-11 | F. Hoffmann-La Roche Ag | Pharmaceutical combinations for treatment of hbv |
| KR20240111795A (ko) * | 2021-11-29 | 2024-07-17 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | B형 간염 바이러스 (hbv) 단백질의 발현을 억제하기 위한 조성물 및 방법 |
| EP4201947A1 (en) | 2021-12-22 | 2023-06-28 | F. Hoffmann-La Roche AG | Process for the backbone deprotection of oligonucleotides containing a terminal alkyl phosphonate group |
| WO2023116764A1 (zh) * | 2021-12-23 | 2023-06-29 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及其用途 |
| US20240309383A1 (en) * | 2023-02-24 | 2024-09-19 | Suzhou Sanegene Bio Inc. | Small interfering rna targeting hbv and uses thereof |
| WO2025199466A1 (en) | 2024-03-22 | 2025-09-25 | Purdue Research Foundation | Liver-specific asialoglycoprotein receptor targeting ligands, conjugates comprising same, and related compositions and methods of use |
| WO2025242321A1 (en) | 2024-05-24 | 2025-11-27 | Glaxosmithkline Intellectual Property (No.3) Limited | Novel use |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040127446A1 (en) | 1992-05-14 | 2004-07-01 | Lawrence Blatt | Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication |
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Rna 간섭의 rna 서열 특이적인 매개체 |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| ATE281838T1 (de) | 2001-05-04 | 2004-11-15 | Technologie Integrale Ltd | Anti-virales reagens |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| WO2003040395A2 (en) | 2001-11-07 | 2003-05-15 | Applera Corporation | Universal nucleotides for nucleic acid analysis |
| EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| CN1257284C (zh) * | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| WO2008016391A2 (en) | 2006-01-31 | 2008-02-07 | The Board Of Trustees Of The Leland Stanford Junior University | Self-complementary parvoviral vectors, and methods for making and using the same |
| DK2094086T3 (da) * | 2006-11-08 | 2013-11-25 | Veritas Bio LLC | Indgivelse in vivo af dobbeltstrenget rna til en målcelle |
| CN101755049B (zh) | 2007-05-29 | 2014-03-12 | 约翰内斯堡威特沃特斯兰德大学 | 初级微rna表达盒 |
| WO2010033225A2 (en) | 2008-09-22 | 2010-03-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications |
| WO2010039543A2 (en) | 2008-09-23 | 2010-04-08 | Traversa Therapeutics, Inc. | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
| KR20110110776A (ko) | 2008-12-18 | 2011-10-07 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| ES2651308T3 (es) * | 2009-10-16 | 2018-01-25 | Glaxo Group Limited | Inhibidores antisentido de HBV |
| US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
| RU2745848C2 (ru) * | 2010-08-17 | 2021-04-01 | Сирна Терапьютикс, Инк. | ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
| SI3505528T1 (sl) * | 2011-04-21 | 2021-04-30 | Glaxo Group Limited | Modulacija izražanja virusa hepatitisa B (HBV) |
| PT2726613T (pt) * | 2011-06-30 | 2018-10-26 | Arrowhead Pharmaceuticals Inc | Composições e métodos para inibição da expressão de genes do vírus da hepatite b |
| AU2012328680A1 (en) | 2011-10-25 | 2014-05-01 | Ionis Pharmaceuticals, Inc. | Antisense modulation of GCCR expression |
| EP2928877B1 (en) | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| US9850486B2 (en) * | 2012-12-14 | 2017-12-26 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of CKAP5 by double-stranded RNA |
| CN103333890B (zh) | 2012-12-21 | 2015-04-15 | 厦门成坤生物技术有限公司 | 治疗乙型病毒性肝炎的rna干扰制剂 |
| PL3114128T3 (pl) | 2014-03-07 | 2019-06-28 | F. Hoffmann-La Roche Ag | Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B |
| GB201408623D0 (en) * | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| CN107109405A (zh) | 2014-06-06 | 2017-08-29 | 索尔斯蒂斯生物有限公司 | 具有生物可逆性和非生物可逆性基团的多核苷酸构建体 |
| CN104059916A (zh) | 2014-06-17 | 2014-09-24 | 湖北医药学院附属太和医院 | 乙肝病毒特异性的microRNA样siRNA序列及其用途 |
| WO2016030863A1 (en) * | 2014-08-29 | 2016-03-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds and methods for treating viral infections |
| TWI769565B (zh) * | 2014-11-10 | 2022-07-01 | 美商阿尼拉製藥公司 | B型肝炎病毒(HBV)iRNA組成物及其用途方法 |
| EP3865576A1 (en) | 2014-12-15 | 2021-08-18 | Dicerna Pharmaceuticals, Inc. | Ligand-modified double-stranded nucleic acids |
| US10689647B2 (en) * | 2015-05-08 | 2020-06-23 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA |
| CN115957337A (zh) | 2015-08-07 | 2023-04-14 | 箭头药业股份有限公司 | 乙型肝炎病毒感染的RNAi疗法 |
| CA3013683C (en) | 2016-03-14 | 2021-07-13 | F. Hoffmann-La Roche Ag | Oligonucleotides for reduction of pd-l1 expression |
| WO2017211791A1 (en) | 2016-06-07 | 2017-12-14 | F. Hoffmann-La Roche Ag | Combination therapy of an hbsag inhibitor and a tlr7 agonist |
| JOP20190015A1 (ar) | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| HRP20231063T1 (hr) * | 2017-10-13 | 2023-12-22 | Novo Nordisk Health Care Ag | Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha |
| EP3684377B1 (en) | 2017-10-20 | 2022-12-07 | Dicerna Pharmaceuticals, Inc. | Methods for treating hepatitis b infection |
| JP2023536999A (ja) | 2020-08-05 | 2023-08-30 | エフ. ホフマン-ラ ロシュ アーゲー | B型肝炎患者のオリゴヌクレオチド処置 |
-
2018
- 2018-10-19 EP EP18868404.7A patent/EP3684377B1/en active Active
- 2018-10-19 BR BR112020007476-4A patent/BR112020007476A2/pt unknown
- 2018-10-19 MA MA50264A patent/MA50264B1/fr unknown
- 2018-10-19 AU AU2018351649A patent/AU2018351649B2/en active Active
- 2018-10-19 UA UAA202002978A patent/UA128786C2/uk unknown
- 2018-10-19 EP EP22201680.0A patent/EP4197544A1/en active Pending
- 2018-10-19 IL IL274040A patent/IL274040B2/en unknown
- 2018-10-19 HR HRP20230023TT patent/HRP20230023T1/hr unknown
- 2018-10-19 RS RS20230047A patent/RS64001B1/sr unknown
- 2018-10-19 LT LTEPPCT/US2018/056801T patent/LT3684377T/lt unknown
- 2018-10-19 ES ES18868404T patent/ES2936863T3/es active Active
- 2018-10-19 CN CN202410274712.6A patent/CN118185936A/zh active Pending
- 2018-10-19 JP JP2020521880A patent/JP7353276B2/ja active Active
- 2018-10-19 PL PL18868404.7T patent/PL3684377T3/pl unknown
- 2018-10-19 SG SG11202003488WA patent/SG11202003488WA/en unknown
- 2018-10-19 CA CA3078960A patent/CA3078960A1/en active Pending
- 2018-10-19 MX MX2020004060A patent/MX2020004060A/es unknown
- 2018-10-19 CR CR20200163A patent/CR20200163A/es unknown
- 2018-10-19 DK DK18868404.7T patent/DK3684377T3/da active
- 2018-10-19 IL IL282881A patent/IL282881B2/en unknown
- 2018-10-19 FI FIEP18868404.7T patent/FI3684377T3/fi active
- 2018-10-19 HU HUE18868404A patent/HUE061122T2/hu unknown
- 2018-10-19 MY MYPI2020001980A patent/MY201698A/en unknown
- 2018-10-19 IL IL319113A patent/IL319113A/en unknown
- 2018-10-19 CN CN201880068102.3A patent/CN111372593B/zh active Active
- 2018-10-19 WO PCT/US2018/056801 patent/WO2019079781A2/en not_active Ceased
- 2018-10-19 PE PE2020000748A patent/PE20220561A1/es unknown
- 2018-10-19 KR KR1020207013967A patent/KR102783206B1/ko active Active
- 2018-10-19 IL IL312809A patent/IL312809B2/en unknown
- 2018-10-19 PT PT188684047T patent/PT3684377T/pt unknown
- 2018-10-19 SI SI201830840T patent/SI3684377T1/sl unknown
-
2020
- 2020-02-14 US US16/790,986 patent/US10799524B2/en active Active
- 2020-04-17 PH PH12020550591A patent/PH12020550591A1/en unknown
- 2020-04-20 CL CL2020001061A patent/CL2020001061A1/es unknown
- 2020-04-24 CO CONC2020/0005135A patent/CO2020005135A2/es unknown
- 2020-07-07 US US16/922,033 patent/US11052105B2/en active Active
- 2020-07-07 US US16/922,007 patent/US11052104B2/en active Active
-
2021
- 2021-05-12 US US17/318,864 patent/US11273173B2/en active Active
-
2022
- 2022-02-02 US US17/649,781 patent/US12564601B2/en active Active
-
2023
- 2023-09-19 JP JP2023151506A patent/JP7645323B2/ja active Active
-
2026
- 2026-02-02 US US19/467,067 patent/US20260151421A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536587A5 (cg-RX-API-DMAC7.html) | ||
| TWI823866B (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| US12303525B2 (en) | Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection | |
| TW202031267A (zh) | S-抗原運輸抑制寡核苷酸聚合物及方法 | |
| US20230119360A1 (en) | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv | |
| AU2017326372B2 (en) | Modified oligonucleotides and methods of use | |
| CN111372593A (zh) | 治疗乙型肝炎感染的方法 | |
| JP2022551269A5 (cg-RX-API-DMAC7.html) | ||
| KR20220148241A (ko) | Pd-l1을 표적화하기 위한 방법 및 조성물 | |
| TW202126809A (zh) | 具有最小氟含量之小干擾rna的化學修飾 | |
| JP2023550061A (ja) | オリゴヌクレオチド及びその抗b型肝炎とd型肝炎ウイルスにおける応用 | |
| JP2022517742A5 (cg-RX-API-DMAC7.html) | ||
| KR20240101580A (ko) | Hbv 치료를 위한 약학 조합물 | |
| JP2022520653A5 (cg-RX-API-DMAC7.html) | ||
| TW202237189A (zh) | 具有增強之肝靶向的s抗原運輸抑制寡核苷酸聚合物之接合物 | |
| WO2025232886A1 (zh) | 一种抑制乙型肝炎病毒的寡核苷酸、缀合物、组合物及其用途 | |
| WO2021130270A1 (en) | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv | |
| CN119662639A (zh) | 抑制乙型肝炎病毒基因表达的siRNA、其缀合物和药物组合物及用途 | |
| HK1077503A1 (zh) | 基於核酸的化合物及其使用方法 | |
| HK1077503B (en) | Nucleic acid-based compounds and methods of use thereof |